Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.

Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities

Open access

Abstract

Within the spectrum of fibrosing interstitial lung diseases (ILDs) is a subset of patients who have inexorable progression of pulmonary fibrosis despite treatment, which is known as the progressive fibrotic phenotype. Although the concept of progressive fibrosing ILD has been applied largely to patients with idiopathic pulmonary fibrosis (IPF), there is now an increasing focus on irreversible progressive fibrosis in a proportion of patients with a range of underlying ILD diagnoses. Evidence has emerged to support a possible role for antifibrotic therapy in these patients. In this Position Paper, we discuss the importance of retaining diagnostic scrutiny within the multidisciplinary team and suggest a multidomain definition for progressive fibrosis. We consider the potential role of antifibrotic drugs as second-line therapy in the treatment algorithm for patients with progressive non-IPF ILD. We highlight risk factors that might predispose individuals to developing progressive fibrosis. Finally, we discuss key uncertainties and future directions for research and clinical practice.

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-2600(20)30355-6

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 75 references

Cited by

See all 349

Metadata

Authors
George, P. M., Spagnolo, P., Kreuter, M., Altinisik, G., Bonifazi, M., Martinez, F. J., Molyneaux, P. L., Renzoni, E. A., Richeldi, L., Tomassetti, S., Valenzuela, C., Vancheri, C., Varone, F., Cottin, V., & Costabel, U.
Affiliations
  • Royal Brompton & Harefield NHS Foundation Trust (GB)
  • University of Padua (IT)
  • Heidelberg University (DE)
  • Marche Polytechnic University (IT)
  • Università Cattolica del Sacro Cuore (IT)
  • Azienda Ospedaliero-Universitaria Careggi (IT)
  • Hospital Universitario de La Princesa (ES)
  • University of Catania (IT)
  • Agostino Gemelli University Polyclinic (IT)
  • Lyon 1 Université (FR)
  • Ruhrlandklinik (DE)
Corresponding author
George, Peter M
Venue
The Lancet Respiratory Medicine
Publisher
Elsevier BV
Published
2020-09
Volume
8
Issue
9
Pages
925-934
ISSN
2213-2600 (ISSN-L)
OpenAlex
W3082751844
Cited by
349
References
75
Citations by year
2026: 31 · 2025: 52 · 2024: 66 · 2023: 51 · 2022: 77 · 2021: 68 · 2020: 4
FWCI
28.12
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc-nd
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Respiratory Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Florence Research (University of Florence) (submittedVersion)
  • Università Politecnica delle Marche (Università Politecnica delle Marche) (submittedVersion)
  • Spiral (Imperial College London) (submittedVersion, cc-by-nc-nd)
  • Padua Research Archive (University of Padova) (submittedVersion)
Funders
  • National Heart, Lung, and Blood Institute
  • AstraZeneca
  • Teva Pharmaceutical Industries
  • Boehringer Ingelheim
  • University of Alabama
  • GlaxoSmithKline
  • Chiesi Farmaceutici
  • Roche Products
  • CSL Behring
  • F. Hoffmann-La Roche
  • Novartis
  • Houston Methodist Hospital
  • Sunovion
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Keywords
progressive fibrosing interstitial lung disease, idiopathic pulmonary fibrosis, progressive fibrosis, antifibrotic therapy, second-line therapy, multidisciplinary diagnosis, treatment algorithm
MeSH terms
Humans, Pulmonary Fibrosis, Research, Lung Diseases, Interstitial, Disease Progression, Biomedical Research

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. https://app.cochat.ai/papers/10.1016/s2213-2600(20)30355-6
The paper
George, P. M., Spagnolo, P., Kreuter, M., Altinisik, G., Bonifazi, M., Martinez, F. J., Molyneaux, P. L., Renzoni, E. A., Richeldi, L., Tomassetti, S., Valenzuela, C., Vancheri, C., Varone, F., Cottin, V., & Costabel, U. (2020). Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(20)30355-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.